Skip to main content
SpringerLink
Log in

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

An Erratum to this article was published on 04 March 2011

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Waterman GN, Yellin O, Swift RA, Mapes R, Eades B, Ackerman E, Berenson JR (2010) A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Ann Hematol. Sep 1 (in press)

  2. Buda G, Orciuolo E, Galimberti S, Cecconi N, Petrini M (2009) Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma. Acta Haematol 122:39–41

    Article  PubMed  Google Scholar 

  3. Dingli D, Rajkumar SV (2010) How best to use new therapies in multiple myeloma. Blood Rev 24:91–100

    Article  PubMed  CAS  Google Scholar 

  4. Plosker GL (2008) Pegylated liposomal doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 68:2535–2551

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Via Roma 67, 56100, Pisa, Italy

    Gabriele Buda, Enrico Orciuolo, Sara Galimberti, Matteo Pelosini & Mario Petrini

Authors
  1. Gabriele Buda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrico Orciuolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Galimberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matteo Pelosini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mario Petrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriele Buda.

Additional information

Gabriele Buda and Enrico Orciuolo contributed equally to this work.

An erratum to this article can be found at http://dx.doi.org/10.1007/s00277-011-1203-6

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buda, G., Orciuolo, E., Galimberti, S. et al. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. Ann Hematol 90, 1115–1116 (2011). https://doi.org/10.1007/s00277-010-1136-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1136-5

Keywords

Search

Navigation